ATE322018T1 - Identifizierung von modulatoren des neurotransmitters xanthurensäure - Google Patents

Identifizierung von modulatoren des neurotransmitters xanthurensäure

Info

Publication number
ATE322018T1
ATE322018T1 AT02767548T AT02767548T ATE322018T1 AT E322018 T1 ATE322018 T1 AT E322018T1 AT 02767548 T AT02767548 T AT 02767548T AT 02767548 T AT02767548 T AT 02767548T AT E322018 T1 ATE322018 T1 AT E322018T1
Authority
AT
Austria
Prior art keywords
identification
novel
targets
selection
xanthurenic acid
Prior art date
Application number
AT02767548T
Other languages
English (en)
Inventor
Serge Gobaille
Michel Maitre
Original Assignee
Univ Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pasteur filed Critical Univ Pasteur
Application granted granted Critical
Publication of ATE322018T1 publication Critical patent/ATE322018T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02767548T 2001-07-05 2002-07-04 Identifizierung von modulatoren des neurotransmitters xanthurensäure ATE322018T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108937A FR2827045B1 (fr) 2001-07-05 2001-07-05 Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments

Publications (1)

Publication Number Publication Date
ATE322018T1 true ATE322018T1 (de) 2006-04-15

Family

ID=8865168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767548T ATE322018T1 (de) 2001-07-05 2002-07-04 Identifizierung von modulatoren des neurotransmitters xanthurensäure

Country Status (12)

Country Link
US (1) US7122326B2 (de)
EP (1) EP1402270B1 (de)
JP (1) JP4230352B2 (de)
AT (1) ATE322018T1 (de)
CA (1) CA2451092A1 (de)
CY (1) CY1105291T1 (de)
DE (1) DE60210309T2 (de)
DK (1) DK1402270T3 (de)
ES (1) ES2260477T3 (de)
FR (1) FR2827045B1 (de)
PT (1) PT1402270E (de)
WO (1) WO2003005038A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US8697674B2 (en) * 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
EP2146209B1 (de) * 2005-04-06 2011-11-16 University of Antwerp Neurodegenerative Marker für Alzheimer-Krankheit
WO2008108994A1 (en) * 2007-03-01 2008-09-12 Carnegie Institution Of Washington Trp/his exchange and kynurenine induced trp transport
CN101945663B (zh) * 2008-02-15 2013-12-04 株式会社津村 抑肝散的生物测定方法
WO2009157083A1 (ja) * 2008-06-27 2009-12-30 株式会社ツムラ 抑肝散のバイオアッセイ方法
JP2014016366A (ja) * 2013-10-02 2014-01-30 Tsumura & Co 抑肝散のバイオアッセイ方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
GB9614823D0 (en) * 1996-07-15 1996-09-04 Pharmacia Spa Recombinant kynurenine-3-hydroxylase enzyme and process for its preparation
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
EP1188056A1 (de) * 1999-06-01 2002-03-20 Merck Frosst Canada & Co. Die verwendung von gabapentin in tests zur bestimmung von gabab rezeptor-modulatoren

Also Published As

Publication number Publication date
JP2004533843A (ja) 2004-11-11
WO2003005038A1 (fr) 2003-01-16
JP4230352B2 (ja) 2009-02-25
US20040157917A1 (en) 2004-08-12
DK1402270T3 (da) 2006-07-24
CY1105291T1 (el) 2010-03-03
EP1402270B1 (de) 2006-03-29
ES2260477T3 (es) 2006-11-01
PT1402270E (pt) 2006-08-31
CA2451092A1 (fr) 2003-01-16
EP1402270A1 (de) 2004-03-31
DE60210309T2 (de) 2006-11-09
FR2827045B1 (fr) 2007-08-10
DE60210309D1 (de) 2006-05-18
US7122326B2 (en) 2006-10-17
FR2827045A1 (fr) 2003-01-10

Similar Documents

Publication Publication Date Title
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
WO2005005462A3 (en) Blys antagonists and uses thereof
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
EA200702208A1 (ru) Ингибиторы дипептидилпептидазы-iv
WO2006076100A3 (en) Tubulin isotype screening in cancer therapy using halichondrin b analogs
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
ATE412642T1 (de) Inhibitoren von p-38-kinase
ES2009728A4 (es) Proceso de aglomeracion de polimeros hidrohinchables por granulado sintereo.
EA200802054A1 (ru) Ингибиторы фермента
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
DE60210309D1 (de) Identifizierung von modulatoren des neurotransmitters xanthurensäure
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
Filho et al. Inhibitory effect of verbascoside isolated from Buddleja brasiliensis Jacq. ex Spreng on prolyl oligopeptidase activity
BRPI0607792A2 (pt) processo para a preparação de moduladores de opióides
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
DE60044655D1 (de) Angereicherte Zellpopulationen des zentralen Nervensystems
BRPI0407913A (pt) antagonistas receptores de ccr-3
WO2005081960A3 (en) Inhibitors of protein tyrosine phosphatase 1b
WO2007041502A3 (en) Methods for determining responsiveness to cancer therapy
AU2003211040A1 (en) The eaat2 promoter and uses thereof
MA27905A1 (fr) Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2001085912A3 (en) Presenilin enhancers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1402270

Country of ref document: EP

REN Ceased due to non-payment of the annual fee